Quick Listen: Scrip's Five Must-Know Things
Executive Summary
In this week's podcast edition of Five Must-Know Things: Bayer takes strategic steps to cut debt; AbbVie confirms internal appointment as CEO; another RIPK1 setback for Denali/Sanofi; new biotech reality in China; and ex-Daiichi Sankyo CEO shares insights into tough decisions.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 23 February 2024, including: Bayer takes strategic steps to cut debt; AbbVie confirms internal appointment as CEO; another RIPK1 setback for Denali/Sanofi; new biotech reality in China; and ex-Daiichi Sankyo CEO shares insights into tough decisions.
This and all our other podcasts are available on the Citeline channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Bayer Cuts Dividend To The Bone To Cut Debt" - Scrip, 21 Feb, 2024.)
(Also see "AbbVie Stays On Script With Michael As Next CEO" - Scrip, 20 Feb, 2024.)
(Also see "Sanofi, Denali Drug Fails In ALS, Adding To RIPK1 Program Setbacks" - Scrip, 16 Feb, 2024.)
(Also see "Hidden Dragon? Investors Return To New China Biotech Reality" - Scrip, 20 Feb, 2024.)
(Also see "From Ranbaxy Crisis To Enhertu Success: How A New CEO Reshaped Daiichi Sankyo" - Scrip, 16 Feb, 2024.)